Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study - Javle, Milind; Roychowdhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Weiss, Karl Heinz; Waldschmidt, Dirk Thomas; Goyal, Lipika; Borbath, Ivan; El-Khoueiry, Anthony; Borad, Mitesh J.; Yong, Wei Peng; et al. (The lancet. Gastroenterology & Hepatology, 2021)
Gesehen am 24.01.2022